Skip to main content

Anebulo Pharmaceuticals, Inc.

corporate_fare Company Profile

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ·Healthcare·CIK 0001815974

Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, including acute cannabis-induced toxicity in children and acute cannabinoid intoxication (ACI) in adults. The company's primary product candidate, selonabant (formerly ANEB-001), is designed to quickly reverse the negative effects of cannabis-induced toxicity and shorten recovery time. Children exposed to cannabis face risks such as Central Nervous System (CNS) depression, respiratory depression, seizures, and coma. Adults with ACI may experience anxiety, panic attacks, agitation, psychosis, and tachycardia. Currently, there are no approved medical treatments specifically for cannabis-induced toxicity. Anebulo Pharmaceuticals is not aware of any competing products further along in development than selonabant for reversing the effects of cannabinoids like delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Cannabis-induced toxicity is a growing health concern in the United States, particularly in states where cannabis is legalized for medical and recreational use. Unintentional or excessive consumption of THC, often through edible products like gummies, candies, and brownies, is a significant cause of THC-related emergency room visits. U.S. hospital emergency rooms have seen a substantial increase in patients with cannabis-related conditions. In 2014, there were an estimated 1.1 million cannabis-related emergency department patient visits. This number is believed to have grown to approximately 1.8 million patients in 2021, based on an analysis of the most recent Nationwide Emergency Department Sample (NEDS) data.

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) is a publicly traded company in the Healthcare sector. Wiseek has independently scored 6 items for ANEB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-02-12, rated 8/10. Across its 6 most recent items scored 7 or higher, the top rating is 10/10, with 6 rated 8 or above. Recent SEC coverage for ANEB spans 10-Q, 8-K, SC TO-I/A.

Recent high-impact activity:

  • Anebulo Pharmaceuticals Reports Q2 FY2026 Results Amidst Voluntary Nasdaq Delisting and Deregistration Plans
  • Anebulo Pharmaceuticals Reports Q2 Results Amidst Nasdaq Delisting Timeline
  • Anebulo Pharmaceuticals to Voluntarily Delist from Nasdaq and Deregister with SEC
  • Anebulo Pharmaceuticals Finalizes Tender Offer, Repurchasing Shares at Significant Premium
  • Anebulo Pharmaceuticals Announces Oversubscribed Tender Offer at Significant Premium

Financial Snapshot

Fiscal year ended June 30, 2025
Net Income
-$8.48M
Diluted EPS
-$0.25
Op. Cash Flow
-$6.35M
Operating Income
-$9.22M
Cash & Equivalents
$11.63M
Debt / Equity
0.00×
Shares Outstanding
41.08M sh
Source: 10-K · filed 2025-09-29 · accession 0001493152-25-016015

Short Interest & Short Volume

FINRA reported short interest of 390,808 shares in ANEB as of the October 30, 2026 settlement, unchanged from the prior period.

Short interest (bi-monthly positions)390,808 shares as of October 30, 2026
Change vs prior period 0.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

No longer listed

ANEB (Anebulo Pharmaceuticals, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed ANEB - Latest Insights

ANEB
Feb 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
ANEB
Feb 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
ANEB
Feb 06, 2026, 9:20 AM EST
Filing Type: 8-K
Importance Score:
10
ANEB
Jan 29, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
8
ANEB
Jan 27, 2026, 9:24 AM EST
Filing Type: 8-K
Importance Score:
9
ANEB
Jan 08, 2026, 9:21 AM EST
Filing Type: SC TO-I/A
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets